Our

Board

Non Executive Chairman Paul Rennie leads Paradigm’s team of Directors, providing guidance and oversight across the company’s activities to deliver shareholder value over the long term.

Cognisant of the fact that some of medicine’s greatest opportunities may never have come to light due to the limitations of the technology of the time, the critical eye of the Paradigm board is invaluable in the company quest to discover the true potential of molecules historically taken for granted.

Paul Rennie
Founder & Chairman

Mr Rennie is recognised as a leading authority in drug development and has been involved in a number of pre-clinical and clinical trial programs over his accomplished career. He was the inaugural COO of Mesoblast and most recently as Executive VP, New Product Development at Mesoblast Ltd. Mr. Rennie has extensive experience in commercialising Intellectual Property.

Paul Rennie
Founder & Chairman

Mr Rennie is recognised as a leading authority in drug development and has been involved in a number of pre-clinical and clinical trial programs over his accomplished career. He was the inaugural COO of Mesoblast and most recently as Executive VP, New Product Development at Mesoblast Ltd. Mr. Rennie has extensive experience in commercialising Intellectual Property.

Dr Donna Skerrett
Executive Director

Dr. Skerrett, has more than 30 years’ experience in transfusion medicine, cellular therapy, and regenerative medicine. She was the CMO of Mesoblast, a stem cell development company (2011-2019), Dir. Transfusion Medicine & Cellular Therapy at Weill Cornell Medical Center, NY (2004-2011), and Ass. Dir. Transfusion Medicine at Columbia University’s NY-Presbyterian Hospital. She has chaired the NY State Governor’s Council on Blood and Transfusion Service and served on the Board of Directors of the Fox Chase Cancer Center. She currently serves in an advisory role on the Board of Visitors for the Lewis Katz School of Medicine of Temple University.

Dr Donna Skerrett
Executive Director

Dr. Skerrett, has more than 30 years’ experience in transfusion medicine, cellular therapy, and regenerative medicine. She was the CMO of Mesoblast, a stem cell development company (2011-2019), Dir. Transfusion Medicine & Cellular Therapy at Weill Cornell Medical Center, NY (2004-2011), and Ass. Dir. Transfusion Medicine at Columbia University’s NY-Presbyterian Hospital. She has chaired the NY State Governor’s Council on Blood and Transfusion Service and served on the Board of Directors of the Fox Chase Cancer Center. She currently serves in an advisory role on the Board of Visitors for the Lewis Katz School of Medicine of Temple University.

Helen Fisher
Non-Executive Director

Helen is CEO and managing director of Cio Capital Impact Fund (BCIF) and Non – Executive Director (NED) and Chair of the Audit and Risk Committee of Calic Limited (ASX: CXL), a company with a platform technology with applications in climate change, water management, biotech, and pharmaceutical areas. Prior to establishing BCIF, Helen was a partner of Deloitte and led Deloitte’s life science practice in Australia for 5 years, having had many years’ experience in the life sciences and health care sector.

Helen Fisher
Non-Executive Director

Helen is CEO and managing director of Cio Capital Impact Fund (BCIF) and Non – Executive Director (NED) and Chair of the Audit and Risk Committee of Calic Limited (ASX: CXL), a company with a platform technology with applications in climate change, water management, biotech, and pharmaceutical areas. Prior to establishing BCIF, Helen was a partner of Deloitte and led Deloitte’s life science practice in Australia for 5 years, having had many years’ experience in the life sciences and health care sector.

John Gaffney
Non-Executive Director

John Gaffney LL.M is a lawyer with over 30 years experience and has undertaken the AICD Company Directors qualification. He brings to the board a compliance and corporate governance background and is experienced in financial services compliance. John also has corporate and commercial experience having worked with a major national law firm as a senior lawyer and also practised as a Barrister at the Victorian Bar. Previously John has been a non executive director of a US based biotechnology company. He is currently a non – executive director of SelfWealth Ltd (ASX: SWF).

John Gaffney
Non-Executive Director

John Gaffney LL.M is a lawyer with over 30 years experience and has undertaken the AICD Company Directors qualification. He brings to the board a compliance and corporate governance background and is experienced in financial services compliance. John also has corporate and commercial experience having worked with a major national law firm as a senior lawyer and also practised as a Barrister at the Victorian Bar. Previously John has been a non executive director of a US based biotechnology company. He is currently a non – executive director of SelfWealth Ltd (ASX: SWF).

Amos Meltzer
Non-Executive Director

Amos Meltzer is a scientist and an intellectual property lawyer with over 25
years of experience in international trade and in commercialising technologies
principally in the life sciences sector. He has presided over life science
research and product development projects clinical trials as well as the
commercialisation of life sciences assets through both licensing and the sale
and marketing of a pharmaceutical product. Previously Amos has served as in
house counsel and IP director at two Nasdaq-listed companies Cgen and Gilat,
as a non-executive director of a biotechnology company Evogene and as VP
of Business Development and then CEO of an ASX-listed biopharmaceutical
company Immuron. Amos currently serves as Chief Operating Officer of neuro-
medical device company Synchron, chairman of the board of surgeons’
education services company Vasculab and as a legal advisor to a number of
ASX listed and private life science companies.

Amos Meltzer
Non-Executive Director

Amos Meltzer is a scientist & IP lawyer with over 25 years of experience in international trade and commercialising technologies, principally in the life sciences sector. He has presided over research & product development projects clinical trials as well as the commercialisation of assets through licensing and the sale & marketing of a pharmaceutical product. Previously Amos has served as in-house counsel & IP director at two Nasdaq-listed companies, as a non-executive director of a biotechnology company & as CEO of an ASX-listed biopharma company. Amos currently serves as CEO of neuro-medical device company Synchron, chairman of the board of surgeons’ education services company, Vasculab and as a legal advisor to a number of ASX listed & private life science companies.

Cancel